BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25014108)

  • 1. In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis.
    García Bustos MF; Barrio A; Prieto GG; de Raspi EM; Cimino RO; Cardozo RM; Parada LA; Yeo M; Soto J; Uncos DA; Parodi C; Basombrío MA
    J Parasitol; 2014 Dec; 100(6):840-7. PubMed ID: 25014108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
    Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
    Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].
    Costa Filho AV; Lucas IC; Sampaio RN
    Rev Soc Bras Med Trop; 2008; 41(4):424-7. PubMed ID: 18853022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
    de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
    J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo activity of perifosine against Leishmania amazonensis.
    Cabrera-Serra MG; Valladares B; Piñero JE
    Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania amazonensis: effects of oral treatment with copaiba oil in mice.
    dos Santos AO; Costa MA; Ueda-Nakamura T; Dias-Filho BP; da Veiga-Júnior VF; de Souza Lima MM; Nakamura CV
    Exp Parasitol; 2011 Oct; 129(2):145-51. PubMed ID: 21771592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
    Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
    J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
    Castro MDM; Cossio A; Velasco C; Osorio L
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005515. PubMed ID: 28379954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
    Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
    Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
    Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
    Zauli-Nascimento RC; Miguel DC; Yokoyama-Yasunaka JK; Pereira LI; Pelli de Oliveira MA; Ribeiro-Dias F; Dorta ML; Uliana SR
    Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
    Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
    Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of pentavalent antimony, amphotericin B, and miltefosine in Leishmania amazonensis-infected macrophages under normoxic and hypoxic conditions.
    Ayres DC; Pinto LA; Giorgio S
    J Parasitol; 2008 Dec; 94(6):1415-7. PubMed ID: 18576874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis.
    Cavalcanti de Queiroz A; Alves MA; Barreiro EJ; Lima LM; Alexandre-Moreira MS
    Exp Parasitol; 2019 Jun; 201():57-66. PubMed ID: 31004571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
    Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
    Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
    Trinconi CT; Reimão JQ; Coelho AC; Uliana SR
    J Antimicrob Chemother; 2016 May; 71(5):1314-22. PubMed ID: 26851606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
    Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
    J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
    Demicheli C; Ochoa R; da Silva JB; Falcão CA; Rossi-Bergmann B; de Melo AL; Sinisterra RD; Frézard F
    Antimicrob Agents Chemother; 2004 Jan; 48(1):100-3. PubMed ID: 14693525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
    Teva A; Porrozzi R; Oliveira-Neto MP; Grimaldi GJ
    J Parasitol; 2005 Aug; 91(4):976-8. PubMed ID: 17089782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-κB pathway.
    Macedo SR; de Figueiredo Nicolete LD; Ferreira Ados S; de Barros NB; Nicolete R
    Int Immunopharmacol; 2015 Sep; 28(1):554-9. PubMed ID: 26218282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.